LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced on July 31, 2026, that it has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module. The module is intended to support access to designated laboratory and scientific services, marking a strategic expansion for the company beyond its core telemedicine offerings.
Through its Venezuelan operating subsidiary, LATAMEDAI VE, LataMed AI will collaborate with IVIC on the design, development, testing, and implementation of a digital interface. This interface is designed to allow authorized business and institutional users to request available laboratory services, schedule appointments, monitor the status of submitted requests, access approved reports and documentation, and complete authorized payment-related processes. The proposed module aims to provide a centralized digital workflow for organizations seeking scientific and laboratory services in sectors such as healthcare, pharmaceuticals, food production, agriculture, and related industries.
The specific services made available through the platform will be determined by IVIC and implemented in accordance with technical, operational, security, and legal requirements established by both parties. LataMed AI will begin by defining the module's functional requirements, user-access procedures, data architecture, payment workflows, document-management capabilities, and the phased testing and implementation process. The parties will also establish procedures for handling, transmitting, storing, and accessing laboratory-related information securely.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated, "This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform."
The initiative aligns with LataMed AI's broader strategy of developing digital infrastructure that connects various participants in the healthcare and scientific-services ecosystem, including patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and institutions. By extending its capabilities to institutional and enterprise workflows, the company aims to demonstrate the versatility of its technology beyond patient-facing telemedicine.
If successfully implemented, management believes the module could serve as a framework adaptable for other institutional and enterprise service environments in Venezuela and other Latin American countries. However, any future expansion would depend on separate agreements, technical readiness, regulatory requirements, and the needs of participating institutions.
The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation date, user adoption level, service volume, revenue, profitability, or expansion to additional institutions. The company will provide updates on development, testing, and implementation as appropriate.
LataMed AI is also developing AI-supported platforms, including CardioAI, PulmoAI, and NeuroAI, designed to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. These platforms remain subject to continued development and regulatory approval.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
